Literature DB >> 7902330

Dipeptidyl peptidase IV (CD26) on human lymphocytes. Synthetic inhibitors of and antibodies against dipeptidyl peptidase IV suppress the proliferation of pokeweed mitogen-stimulated peripheral blood mononuclear cells, and IL-2 and IL-6 production.

D Reinhold1, U Bank, F Bühling, K Neubert, T Mattern, A J Ulmer, H D Flad, S Ansorge.   

Abstract

In the present report, we describe that synthetic inhibitors of and polyclonal and monoclonal antibodies against the membrane ectoenzyme dipeptidyl peptidase IV (DP IV, CD26) inhibit the production of IL-2 and IL-6 and, concomitantly, DNA synthesis of pokeweed mitogen-stimulated peripheral blood mononuclear cells (PBMC). The release of IL-1 and TNF-alpha, was not influenced under these conditions. The data support the hypothesis that DP IV, possibly in conjunction with other peptidase, is involved in the regulation of activation and proliferation of T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7902330     DOI: 10.1016/S0171-2985(11)80223-8

Source DB:  PubMed          Journal:  Immunobiology        ISSN: 0171-2985            Impact factor:   3.144


  6 in total

Review 1.  Cardiovascular impact of drugs used in the treatment of diabetes.

Authors:  Chris R Triggle; Hong Ding
Journal:  Ther Adv Chronic Dis       Date:  2014-11       Impact factor: 5.091

2.  Inhibitors of dipeptidyl peptidase IV induce secretion of transforming growth factor-beta 1 in PWM-stimulated PBMC and T cells.

Authors:  D Reinhold; U Bank; F Bühling; U Lendeckel; J Faust; K Neubert; S Ansorge
Journal:  Immunology       Date:  1997-07       Impact factor: 7.397

3.  Induction of the membrane alanyl aminopeptidase gene and surface expression in human T-cells by mitogenic activation.

Authors:  U Lendeckel; T Wex; D Reinhold; T Kähne; K Frank; J Faust; K Neubert; S Ansorge
Journal:  Biochem J       Date:  1996-11-01       Impact factor: 3.857

4.  Antibody-induced modulation of CD26 surface expression.

Authors:  T Mattern; C Reich; M Duchrow; S Ansorge; A J Ulmer; H D Flad
Journal:  Immunology       Date:  1995-04       Impact factor: 7.397

Review 5.  Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials.

Authors:  Jixin Zhong; Quan Gong; Aditya Goud; Srividya Srinivasamaharaj; Sanjay Rajagopalan
Journal:  J Diabetes Res       Date:  2015-05-14       Impact factor: 4.011

Review 6.  Dpp4 inhibition as a therapeutic strategy in cardiometabolic disease: Incretin-dependent and -independent function.

Authors:  Quan Gong; Sanjay Rajagopalan; Jixin Zhong
Journal:  Int J Cardiol       Date:  2015-06-27       Impact factor: 4.164

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.